| 20th Dec 2021 7:00 am |
RNS |
Saphnelo recommended for EU approval for SLE |
| 15th Dec 2021 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 9th Dec 2021 7:00 am |
RNS |
Evusheld US FDA EUA |
| 7th Dec 2021 7:00 am |
RNS |
AstraZeneca, Ionis to collaborate on eplontersen |
| 1st Dec 2021 3:00 pm |
RNS |
Block listing Interim Review |
| 1st Dec 2021 3:00 pm |
RNS |
Total Voting Rights |
| 30th Nov 2021 7:00 am |
RNS |
Lynparza granted FDA Priority Review for OlympiA |
| 15th Nov 2021 4:00 pm |
RNS |
Director/PDMR Shareholding |
| 12th Nov 2021 7:00 am |
RNS |
AZN: Year to date and Q3 2021 results |
| 1st Nov 2021 3:00 pm |
RNS |
Total Voting Rights |
| 1st Nov 2021 7:00 am |
RNS |
AstraZeneca to transfer rights to Eklira, Duaklir |
| 25th Oct 2021 7:00 am |
RNS |
Imfinzi improved survival in biliary tract cancer |
| 18th Oct 2021 7:00 am |
RNS |
AZ recommends ADS holders reject mini-tender offer |
| 15th Oct 2021 7:00 am |
RNS |
Imfinzi & tremelimumab improved OS in liver cancer |
| 11th Oct 2021 7:00 am |
RNS |
AZD7442 PhIII trial positive in COVID outpatients |
| 4th Oct 2021 7:00 am |
RNS |
Enhertu granted BTD for breast cancer |
| 1st Oct 2021 3:00 pm |
RNS |
Total Voting Rights |
| 30th Sep 2021 4:00 pm |
RNS |
Director/PDMR Shareholding |
| 29th Sep 2021 7:00 am |
RNS |
AstraZeneca to fully acquire Caelum Biosciences |
| 28th Sep 2021 7:00 am |
RNS |
Saphnelo approved in Japan for SLE |
| 24th Sep 2021 7:00 am |
RNS |
Lynparza PROpel trial meets primary endpoint |
| 23rd Sep 2021 7:00 am |
RNS |
Board Committee Change |
| 23rd Sep 2021 7:00 am |
RNS |
New Sustainability Committee of the Board |
| 21st Sep 2021 7:00 am |
RNS |
AstraZeneca $360m Irish manufacturing investment |
| 20th Sep 2021 7:00 am |
RNS |
Enhertu reduced risk of disease progression by 72% |
| 9th Sep 2021 4:00 pm |
RNS |
Imfinzi improves survival in NSCLC in POSEIDON |
| 9th Sep 2021 7:00 am |
RNS |
PT027 PhIII asthma trials met primary endpoints |
| 3rd Sep 2021 7:00 am |
RNS |
Ultomiris approved in EU for children with PNH |
| 1st Sep 2021 3:00 pm |
RNS |
Total Voting Rights |
| 26th Aug 2021 7:05 am |
RNS |
Forxiga approved in Japan for CKD |
| 26th Aug 2021 7:00 am |
RNS |
ALXN1840 Wilson Phase III met primary endpoint |
| 20th Aug 2021 7:05 am |
RNS |
Update on Ultomiris Phase III ALS trial |
| 20th Aug 2021 7:00 am |
RNS |
AZD7442 prophylaxis trial met primary endpoint |
| 16th Aug 2021 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 11th Aug 2021 2:35 pm |
RNS |
Update on US review of roxadustat |
| 9th Aug 2021 7:05 am |
RNS |
Forxiga approved in the EU for CKD |
| 9th Aug 2021 7:00 am |
RNS |
Enhertu head-to-head trial meets primary endpoint |
| 2nd Aug 2021 3:00 pm |
RNS |
Total Voting Rights |
| 2nd Aug 2021 7:00 am |
RNS |
Saphnelo approved in the US for SLE |
| 29th Jul 2021 7:00 am |
RNS |
AZN: H1 2021 Results |
